Artwork for podcast Pathfinders in Biopharma
When to Call it Quits: VCs Making Tough Decisions in a Tough Market
Episode 1213th July 2023 • Pathfinders in Biopharma • RBC Capital Markets
00:00:00 00:32:01

Share Episode

Shownotes

While the public biotech markets remain volatile, VCs continue to raise new funds. Are we witnessing a renaissance in the private capital markets? The bankruptcy rate of biotechs is historically among the lowest of US publicly traded companies, however, companies are failing and there is still a widely held belief that too many biotech companies are in existence today. What are the hallmarks of companies that will not make it, and when does it make sense to ‘call it’ or divest?

In this episode of Pathfinders in Biopharma, hear from Jerel Davis, Managing Director at Versant Ventures, Otello Stampacchia, Founder & Managing Director at Omega Funds, Simeon George, CEO & Managing Partner at SR One and RBC’s Noël Brown, Head of US Biotechnology Investment Banking, for a roundtable discussion on navigating the path to growth.

Follow

Links

Chapters

Video

More from YouTube